Back to Search
ARCHIE TSE, MD
MD
Medical Oncology Physician
NPI: 1982675617Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
225454(NY)
Research & Publications (20)
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
PMID 18820127·Mol Pharmacol·2009
8-other
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies.
PMID 19221752·Cancer Chemother Pharmacol·2009
3-trial
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors.
PMID 18927314·Clin Cancer Res·2008
3-trial
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
PMID 17255282·Clin Cancer Res·2007
7-preclinical
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
PMID 15374978·Cancer Res·2004
8-other
Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival.
PMID 19491285·Ann Oncol·2009
3-trial
Differential regulation of betacellulin and heparin-binding EGF-like growth factor in cultured zebrafish ovarian follicle cells by EGF family ligands.
PMID 19000772·Comp Biochem Physiol A Mol Integr Physiol·2009
7-preclinical
Aurora B kinase regulates the postmitotic endoreduplication checkpoint via phosphorylation of the retinoblastoma protein at serine 780.
PMID 19225156·Mol Biol Cell·2009
8-other
Dose and chemical modification considerations for continuous cyclic AMP analog delivery to the injured CNS.
PMID 19397425·J Neurotrauma·2009
7-preclinical
Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors.
PMID 18443904·Breast Cancer Res Treat·2009
8-other
Laparoscopic partial nephrectomy: the University of Saskatchewan (Regina division) experience.
PMID 19424463·Can Urol Assoc J·2009
8-other
A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastatic pancreatic cancer.
PMID 19451750·Pancreatology·2009
3-trial
Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.
PMID 18616651·Am J Gastroenterol·2008
8-other
Administration of melatonin mixed with soft food and liquids for children with neurodevelopmental difficulties.
PMID 18754762·Dev Med Child Neurol·2008
2-rct
Methoxylation of 3',4'-aromatic side chains improves P-glycoprotein inhibitory and multidrug resistance reversal activities of 7,8-pyranocoumarin against cancer cells.
PMID 18313307·Bioorg Med Chem·2008
8-other
Adaptive changes in the injured spinal cord and their role in promoting functional recovery.
PMID 18387259·Neurol Res·2008
6-review
Genetic polymorphisms of adiponectin and tumor necrosis factor-alpha and nonalcoholic fatty liver disease in Chinese people.
PMID 18565022·J Gastroenterol Hepatol·2008
8-other
AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
PMID 18790776·Mol Cancer Ther·2008
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1275 YORK AVE
NEW YORK, NY 10021 - Phone
- (646) 227-3813
Quick Facts
- NPI
- 1982675617
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile